Alumis (ALMS) Non Operating Income (2023 - 2026)
Alumis' (ALMS) quarterly Non Operating Income came in at $4.9 million in Q2 2026, down 97.45% year-over-year from $191.3 million in Q2 2025, and up 38.79% quarter-over-quarter from $3.5 million in Q4 2025.
Analysis
Alumis (ALMS) Non Operating Income (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Non Operating Income for 4 consecutive years, with $4.9 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Non Operating Income fell 97.45% year-over-year to $4.9 million in Q2 2026; TTM through Jun 2026 was $204.2 million, a 0.6% increase from a year earlier, with the FY2025 full-year figure at $201.9 million, up 2996.43% from the prior year.
- Non Operating Income was $4.9 million for Q2 2026 at Alumis, up from $3.5 million in the prior quarter.
- Over five years, Non Operating Income peaked at $191.3 million in Q2 2025 and troughed at -$2.3 million in Q1 2024.
- A 4-year average of $18.0 million and a median of $3.0 million in 2025 frame the typical range for Non Operating Income.
- Across the five-year window, Non Operating Income slumped 127.59% in 2024 and jumped 52083.42% in 2025, its largest moves.
- Over 4 years, Non Operating Income stood at $832000.0 in 2023, then jumped by 364.3% to $3.9 million in 2024, then dropped by 9.03% to $3.5 million in 2025, then surged by 38.79% to $4.9 million in 2026.
- The last three Non Operating Income figures came in at $4.9 million (Q2 2026), $3.5 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Alumis | 1.27 Bn | 765.76 Mn | - | 4.88 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.88 Mn |
| Dec 31, 2025 | 3.51 Mn |
| Sep 30, 2025 | 4.54 Mn |
| Jun 30, 2025 | 191.30 Mn |
| Mar 31, 2025 | 2.57 Mn |
| Dec 31, 2024 | 3.86 Mn |
| Sep 30, 2024 | 5.28 Mn |
| Jun 30, 2024 | -368,000.00 |
| Mar 31, 2024 | -2.26 Mn |
| Dec 31, 2023 | 832,000.00 |
| Sep 30, 2023 | 382,000.00 |
| Jun 30, 2023 | 1.33 Mn |